Asia Pharma R&D Leaders 2010

　March 4-5 , 2010 | InterContinental Pudong Shanghai

Asia Pharma R&D Leaders 2010

Home | 中文 　

Overview

The Pharma and biotech sectors are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. Big pharmaceutical companies are being forced to globalize their R&D operations, especially to emerging markets.

Led by China and India, Asia is growing into a drug manufacturing powerhouse and a leading source of drug discovery and high-end innovation during the recent years. Big Pharma companies now rank China as the best location for conducting R&D in Asia, followed by India, Korea and Taiwan, respectively.

Looking more closely at China, although the recession has slowed Big Pharma's investment, the country's wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities.

Asia Pharma R&D Leaders 2010 Speakers

Greg Wiederrecht, Ph.D.
Vice President External Scientific Affairs
Merck & Co. Inc

Hans-Joachim Bohm, Ph.D.
Head of Global Chemistry
Hoffman La-Roche

Steven Wick, Ph.D.
Vice President Research & Development, 3M Drug Delivery Systems

Steve Yang, Ph.D.
Vice President, Head of Asia R&D, Pfizer Pharma Therapeutics R&D

Li Chen, Ph.D.
Chief Scientific Officer
Roche R&D Center, China

Tony Zhang, Ph.D.
Managing Director and Site Head of China
Eli Lilly Global R&D

Josep Prous, Jr., Ph.D., MBA
Vice President & Chief Scientific Officer, Thomson Reuters

Samantha Du, Ph.D.
CEO
Hutchison MediPharma

Peng Wang, Ph.D.
Chief Scientific Officer
Simcere Pharmaceutical Group

Richard Wang, Ph.D.
Director of Strategic Alliance and Collaboration for Asia
AstraZeneca Innovation Center China

Daniel Grant, Ph.D.
Head of Strategic Alliances
Pfizer Australia

Yoshiki Nishikawa, Ph.D.
Director, Head of R&D, Kobe Pharma Research Institute
Boehringer Ingelheim

Thomas Evans, M.D.
Head of Translational Sciences
China Novartis Institute of Biomedical Research

Daniel Lee, Ph.D.
Senior Director, Translational Research
GlaxoSmithKline

Jingsong Wang, M.D.
Director of Discovery Medicine & Clinical Pharmacology
Bristol-Myers Squibb

Marcus Doege, Ph.D.
Global Marketing Director Genome Sequencing
Roche Applied Science

Jeffrey McKown, Ph.D.
Global Technology Director, Grace Davison Discovery Sciences

Christopher Ung, MS MBA
Vice President, Global Central Laboratories, Quintiles Translational

Jessica Liu, M.D.
Senior Director of Clinical Operations, Asia Pacific Rim, INC Research

Steven Hou, Ph.D.
Vice President, Rundo-Cronova

Kim Andersen, Ph.D.
Vice President R&D
Lundbeck AS

Yan Wu, M.D.
Medical and Clinical Development Director
Biogen Idec

Chen Chen, Ph.D.
SVP of Chemistry, Sundia Meditech

Jennifer Hu, Ph.D.
Director, Licensing and External Research, Merck Sharp & Dohme (China) Ltd

Julian Henschke, Ph.D.
R&D Director
ScinoPharm Kunshan

Chunlin Chen Ph.D.
CEO
Shanghai Medicilon Inc.

Angela Chen Ph.D.
Head of Business Development
HD Biosciences

Sanjeev K. Chaudhry, Ph.D.

CEO
Super Religare Laboratories Limited

Graham Bunn, Ph.D.
Vice President, Partnership & Alliances
Medidata Solutions Worldwide

Esther Lim, J.D.
Managing Partner, Finnegan

Ningling Wang, J.D.
Partner, Finnegan

Young Jack Lee, Ph.D.
President
LSK Global Pharma Services, Korea

Jikai Liu, Ph.D.
Director of Kunming Institute of Botany
Chinese Academy of Sciences

Brian Mi, Ph.D., MBA
Principal, China Consulting & Services
IMS Health

Jianyi Sun
Vice President, Customer Excellence
Thermo Fisher Scientific (China)

Fintan Walton, Ph.D.
Chief Executive Officer and Founder
PharmaVentures UK

Hui Hsing Ma, MBA
General Partner
TVM-Capital

Junbo Ge, M.D.
Professor & Dean of Department Of Cardiology
Fudan University Zhongshan Hospital

Jin Li, M.D.
Professor & Dean of Department of Medical Oncology
Fudan University Cancer Hospital

Chuanzhen Lu, M.D.
Professor, Dean of Department of Neurology
Fudan University Huashan Hospital

Su-Yu Chien, RPh, M.S.
President
Taiwan Society of Health - System Pharmacists (TSHP)

Program highlights

Asian strategies and China focus: managing pharma R&D activities cost and time effectively
Gain market competitiveness in Asia: deriving maximum value from M&A and licensing deals
New approaches in pharma R&D: next generation small molecule therapeutics
Diversifying product pipelines: rethinking about natural products; exploring biologics
Global experience in clinical trials success: strategies to enhance clinical trial design
E-clinical trials: leveraging EDC to enhance clinical trials efficiency
How biotech companies can thrive in the prolonged funding drought
Realizing personalized medicine through translational research
Showcase of novel therapeutics for oncology, cardiology, neurology,
inflammation and immunology

Benefits of attending

Learn how major innovation breakthrough in world pharma industry will affect your bottom-line. Your most immediate business questions are being tackled by an unrivalled line-up of speakers and panel members.

Key benefits are:

Discover how to bring drugs to market in a timely and cost effective manner
Examine the latest case studies employed by leading drug companies
Network with 200+ industry leaders in drug discovery from all around the world
Explore funding opportunities to fuel your research and development
Establish partnership with local organizations to coordinate your operations in Asia
Benchmark your company's performance against others
Find partners to conduct clinical trials in Asia